Bruehlman Ronald E 4

What Happened Ronald E. Bruehlman, a director of GoodRx Holdings, Inc. (GDRX), was granted 4,642 deferred stock units on May 27, 2026. The units were reported at $0 per unit (transaction code A — award/grant), so the filing shows $0 as the acquisition price/value. This was a compensation award rather than an open‑market purchase or sale.

Key Details

• Transaction date and price: 2026-05-27, award of 4,642 units at $0.00 each (code A).
• Filed with SEC: Form 4 filed 2026-05-29 for the 2026-05-27 transaction (appears timely).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote (F1): These are deferred stock units (each unit = contingent right to one Class A share). Vesting: 2% of the underlying shares vest on May 31, 2026; the remaining 98% vest in substantially equal monthly installments on the last day of each month over the next 7 months, subject to continued service. Settlement occurs on the earliest of (i) Dec 31, 2031; (ii) separation from service; (iii) change in control; (iv) death; or (v) disability, per the company’s Deferred Compensation Plan for Directors.

Context Deferred stock units are a form of compensation and represent a future contingent right to receive shares if vesting/settlement conditions are met. Awards like this reflect director compensation and are not the same signal as an open‑market buy or sell by an insider.